SCHEMBL13181704

SCHEMBL13181704

CNNCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23731655 0.77
SCHEMBL4609598 0.71
SCHEMBL8002040 0.69
SCHEMBL278782 0.67
SCHEMBL19259048 0.65
SCHEMBL13702622 0.64
Hydrochloric Acid SCHEMBL15004718 0.64
SCHEMBL16128996 0.64
SCHEMBL6845221 0.64
SCHEMBL23161541 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4245296-B1 COMPOSITIONS IN THE FORM OF DISSOLVABLE SOLID STRUCTURES PROCTER & GAMBLE (US) 2024-07-17 EP disclosed
US-20230312620-A1 PHOSPHOLIPID NIPPON FINE CHEMICAL CO., LTD. (JP) 2023-10-05 US disclosed
EP-4241842-A2 NOVEL TREATMENT OF MITOCHONDRIAL DISEASES KHONDRION IP B.V. (NL) 2023-09-13 EP disclosed
WO-2023130070-A2 CARBOLINE COMPOUNDS AND USE THEREOF PTC THERAPEUTICS, INC. (US) 2023-07-06 WO disclosed
US-20230174459-A1 LIPID CONTAINING FORMULATIONS ARBUTUS BIOPHARMA CORPORATION (US) 2023-06-08 US disclosed
US-20230151128-A1 NEAR INFRARED (NIR) LIGHT CONTROLLED RUTHENIUM CATALYZED OLEFIN METATHESIS NATIONAL SCIENCE FOUNDATION 2023-05-18 US disclosed
US-20230119068-A1 METHODS FOR RAPID SYNTHESIS OF PYRANOANTHOCYANINS OHIO STATE INNOVATION FOUNDATION 2023-04-20 US disclosed
EP-4134104-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM Eubulus Biotherapeutics Inc. (CN) 2023-02-15 EP disclosed
WO-2022159454-A1 BET SUBFAMILY INHIBITORS AND METHODS USING SAME BAYLOR COLLEGE OF MEDICINE (US) 2022-07-28 WO disclosed
EP-3950685-A1 PYRAZOLOPYRIDINE COMPOUND AS RET INHIBITOR AND APPLICATION THEREOF Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory (CN) 2022-02-09 EP disclosed
US-7303921-B2 Method to assay coenzyme Q10 in blood plasma or blood serum LITTARRU GIAN PAOLO 2007-12-04 US disclosed
US-20070275908-A1 Methods and Compositions for the Enzymatic Synthesis of Gangliosides NEOSE TECHNOLOGIES, INC. (US) 2007-11-29 US disclosed
US-7298494-B2 Methods and systems for interferometric analysis of surfaces and related applications ZYGO CORPORATION (US) 2007-11-20 US disclosed
WO-2007121924-A2 BISADENOSINE COMPOUNDS AS ADENOSINE A2A RECEPTOR AGONISTS NOVARTIS AG (CH) 2007-11-01 WO disclosed
US-7211666-B2 Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-05-01 US disclosed
US-20070061385-A1 System to manage and store backup and recovery meta data APTARE, INC. (CA) 2007-03-15 US disclosed
US-20070020625-A1 Sequence of the photorhabdus luminescens strain tt01 genome and uses DUCHAUD ERIC 2007-01-25 US disclosed
US-20070012895-A1 Highly concentrated, self-emulsifying preparations containing organopolysiloxanes and alkyl ammonium compounds and their use in aqueous systems RUDOLF GMBH & CO. KG CHEMISCHE FABRIK (DE) 2007-01-18 US disclosed
US-20070014690-A1 Multichamber device for processing of biological samples using high pressure BBI BIOSEQ, INC., A MASSACHUSETTS CORPORATION 2007-01-18 US disclosed
WO-2000078728-A1 NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS NEUROSEARCH A/S (DK) 2000-12-28 WO disclosed